UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Journal of clinical oncology, 2018-04, Vol.36 (11), p.1080-1087

2018

Volltextzugriff (PDF)

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

The New England journal of medicine, 2015-08, Vol.373 (8), p.737-746

2015

Volltextzugriff (PDF)

Characteristics and outcomes of patients with multiple myeloma at the Uganda Cancer Institute

African health sciences, 2021-03, Vol.21 (1), p.67-74

2021

Volltextzugriff (PDF)

Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis

Current opinion in hematology, 2007-09, Vol.14 (5), p.468-480

2007

Volltextzugriff (PDF)

Drug Insight: vascular disrupting agents and angiogenesis-novel approaches for drug delivery

Nature clinical practice. Oncology, 2006-12, Vol.3 (12), p.682-692

2006

Volltextzugriff (PDF)

Clinicopathological characteristics and treatment outcomes of oesophageal cancer patients in Uganda

Ecancermedicalscience, 2023, Vol.17, p.1576-1576

2023

Volltextzugriff (PDF)

MP84-15 NATIONAL TRENDS OF LOCAL ABLATIVE THERAPY AMONG YOUNG PATIENTS WITH SMALL RENAL MASSES

The Journal of urology, 2015-04, Vol.193 (4), p.e1064-e1064

2015

Volltextzugriff (PDF)

Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?

Journal of clinical oncology, 2006-04, Vol.24 (10), p.1485-1488

2006

Volltextzugriff (PDF)

Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds

Current oncology reports, 2005-03, Vol.7 (2), p.90-95

2005

Volltextzugriff (PDF)

The Tempus TIME trial portal and clinical trial enrollment

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.1583-1583

2023

Volltextzugriff (PDF)

Impact of Exigent Research Network’s partnership with the Tempus AI TIME Program on the screening and matching of patients for clinical trials

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e13599-e13599

2024

Volltextzugriff (PDF)

Pilot study for the use of wearable devices for patients undergoing oral chemotherapy

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e14103-e14103

2020

Volltextzugriff (PDF)

The TIME Trial Network to facilitate rapid clinical trial activation, patient screening, and enrollment in molecularly targeted trials

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1563-1563

2021

Volltextzugriff (PDF)

Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5081-5081

2022

Volltextzugriff (PDF)

Operational metrics for the ELAINE II study combining a traditional approach with a just-in-time model

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1504-1504

2022

Volltextzugriff (PDF)

Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e13588-e13588

2021

Volltextzugriff (PDF)

Patterns of metastases, treatment (tx), and outcomes in bone predominant (BP) metastatic urothelial carcinoma (mUC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e16523-e16523

2018

Volltextzugriff (PDF)

Outcomes in bone predominant (BP) urothelial carcinoma (UC)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.441-441

2018

Volltextzugriff (PDF)

Prostate cancer burden at the Uganda Cancer Institute (UCI)

Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.246-246

2015

Volltextzugriff (PDF)

Promising systemic therapy for renal cell carcinoma

Current treatment options in oncology, 2005-10, Vol.6 (5), p.357-365

2005

Volltextzugriff (PDF)

HCRN GU14-188: Neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS4578-TPS4578

2016

Volltextzugriff (PDF)

Impact of metformin on prostate cancer (PC) outcomes in the E3805 CHAARTED trial

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.181-181

2017

Volltextzugriff (PDF)

Lower PSA at 7 months is prognostic for improved overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel (D)

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.137-137

2017

Volltextzugriff (PDF)

Olaratumab and doxorubicin versus doxorubicin alone in soft tissue sarcoma

The Lancet (British edition), 2016-06, Vol.388 (10043), p.488-497

2016

Volltextzugriff (PDF)

Inhibition of the IGF pathway in metastatic castrate resistant prostate cancer (CRPC): Results from a phase II study of OSI-906 (linsitinib)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e16022-e16022

2013

Volltextzugriff (PDF)

1 – 25 von 119

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(107)
Mit Volltextzugriff
(101)

Publikationsform

Sprache

Englisch
(119)

Erscheinungsjahr

n.n

Thema

Science & Technology
(61)
Life Sciences & Biomedicine
(47)
Humans
(27)
Animals
(15)
Male
(11)
Oncology
(11)
General & Internal Medicine
(10)
Medicine, General & Internal
(9)
Physics
(9)
Physical Sciences
(8)
Mice
(7)
Exact Sciences And Technology
(6)
Risk Factors
(6)
Biochemistry & Molecular Biology
(5)
Gene Expression
(5)
Multidisciplinary Sciences
(5)
Neoplasms - Drug Therapy
(5)
Neurosciences & Neurology
(5)
Patients
(5)
Physics Of Gases, Plasmas And Electric Discharges
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(25)
Annals Of Internal Medicine
(9)
Blood
(4)
Science
(3)
Cancer
(2)
Cns Spectrums
(2)
Gastroenterology
(2)
Ieee Transactions On Plasma Science
(2)
Landscape History
(2)
Medicine And Science In Sports And Exercise
(2)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Characteristics and outcomes of patients with multiple myeloma at the Uganda Cancer Institute

Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis

Drug Insight: vascular disrupting agents and angiogenesis-novel approaches for drug delivery

Clinicopathological characteristics and treatment outcomes of oesophageal cancer patients in Uganda

MP84-15 NATIONAL TRENDS OF LOCAL ABLATIVE THERAPY AMONG YOUNG PATIENTS WITH SMALL RENAL MASSES

Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?

Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds

The Tempus TIME trial portal and clinical trial enrollment

Impact of Exigent Research Network’s partnership with the Tempus AI TIME Program on the screening and matching of patients for clinical trials

Pilot study for the use of wearable devices for patients undergoing oral chemotherapy

The TIME Trial Network to facilitate rapid clinical trial activation, patient screening, and enrollment in molecularly targeted trials

Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial

Operational metrics for the ELAINE II study combining a traditional approach with a just-in-time model

Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials

Patterns of metastases, treatment (tx), and outcomes in bone predominant (BP) metastatic urothelial carcinoma (mUC)

Outcomes in bone predominant (BP) urothelial carcinoma (UC)

Prostate cancer burden at the Uganda Cancer Institute (UCI)

Promising systemic therapy for renal cell carcinoma

HCRN GU14-188: Neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC)

Impact of metformin on prostate cancer (PC) outcomes in the E3805 CHAARTED trial

Lower PSA at 7 months is prognostic for improved overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel (D)

Olaratumab and doxorubicin versus doxorubicin alone in soft tissue sarcoma

Inhibition of the IGF pathway in metastatic castrate resistant prostate cancer (CRPC): Results from a phase II study of OSI-906 (linsitinib)

Aktive Filter

Suchergebnisse filtern